NCT04019652View on ClinicalTrials.gov

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

November 19, 2015

Primary Completion Date

December 23, 2015

Study Completion Date

December 23, 2015

Conditions
HypertensionMineralocorticoid Receptor Antagonist
Interventions
DRUG

CS-3150

Single, oral administration; 10-mg or 40-mg dose

DRUG

Moxifloxacin

Single, oral administration; 400 mg-tablet

DRUG

Placebo matching moxifloxacin tablet

Placebo tablets matching moxifloxacin tablets

DRUG

Placebo matching CS-3150

Placebo tablets matching CS-3150 tablets

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY